Canada markets closed

Medexus Pharmaceuticals Inc. (MDP.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
7.30-0.10 (-1.35%)
At close: 3:51PM EDT
Full screen
Previous Close7.40
Open7.45
Bid7.29 x 0
Ask7.37 x 0
Day's Range7.22 - 7.45
52 Week Range2.39 - 9.75
Volume33,671
Avg. Volume89,446
Market Cap139.367M
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-1.81
Earnings DateJun. 21, 2021 - Jun. 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
  • Medexus Announces Conference Participation for April 2021
    GlobeNewswire

    Medexus Announces Conference Participation for April 2021

    TORONTO and CHICAGO and MONTREAL, April 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731), today announced that Ken d’Entremont, CEO, and Roland Boivin, CFO, will be participating in the Bloom Burton & Co. Healthcare Investor Conference as well as the Stifel 2021 Canada Cross Sector Insight Conference in the month of April. Bloom Burton & Co. Healthcare Investor Conference Date: Tuesday, April 20, 2021Time: 11a.m. ETRegister for the virtual conference: click here The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings. Stifel 2021 Canada Cross Sector Insight Conference Medexus will also be participating in several one-on-one investor meetings on Wednesday, April 21, 2021 at the Stifel 2021 Canada Cross Sector Insight Conference. Investors should contact their Stifel representatives for more details. About Medexus Pharmaceuticals Inc. Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action. For more information, please contact: Ken d’Entremont, Chief Executive OfficerMedexus Pharmaceuticals Inc.Tel.: 905-676-0003E-mail: ken.dentremont@medexus.com Roland Boivin, Chief Financial OfficerMedexus Pharmaceuticals Inc.Tel.: 514-344-8765E-mail: roland.boivin@medexus.com Investor Relations (U.S.):Crescendo Communications, LLCTel: +1-212-671-1020E-mail: mdp@crescendo-ir.com Investor Relations (Canada):Tina ByersAdelaide CapitalTel: 905-330-3275E-mail: tina@adcap.caNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

  • Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees
    GlobeNewswire

    Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees

    TORONTO, CHICAGO and MONTREAL, March 31, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to report that the Company’s non-executive directors were permitted to make a one-time, irrevocable election, to receive restricted share units (“RSUs”) in lieu of cash director fees for the 2021 calendar year and all non-executive directors have made such election. The RSUs will be issued in accordance with the Company’s 2018 omnibus equity incentive plan and on the first day following each quarter-end, with the number of RSUs determined by reference to the cash fees that would otherwise be payable to the applicable director, and the volume-weighted average trading price of the Company’s common shares. The RSUs will vest immediately and entitle the applicable holder to receive one common share of the Company at a price of $0.01 per common share. About Medexus Pharmaceuticals Inc. Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action. For more information, please contact: Ken d’Entremont, Chief Executive OfficerMedexus Pharmaceuticals Inc.Tel.: 905-676-0003E-mail: ken.dentremont@medexus.com Roland Boivin, Chief Financial OfficerMedexus Pharmaceuticals Inc.Tel.: 514-344-8765E-mail: roland.boivin@medexus.com Investor Relations (U.S.):Crescendo Communications, LLCTel: +1-212-671-1020Email: mdp@crescendo-ir.com Investor Relations (Canada):Tina ByersAdelaide Capital Tel: 905-330-3275E-mail: tina@adcap.ca Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

  • Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021
    GlobeNewswire

    Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021

    TORONTO, CHICAGO and MONTREAL, March 08, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that Ken d’Entremont, Chief Executive Officer, and Roland Boivin, Chief Financial Officer of Medexus, will be conducting 1x1 meetings with investors during the 33rd Annual Roth Conference being held virtually from March 15th – March 17th, 2021. This year’s event will consist of 1-on-1 / small group meetings, analyst-selected virtual fireside chats, thematic industry panels, and selected Companies on-demand presentations. Institutional investors interested in one-on-one meetings with Medexus management should contact their ROTH Capital institutional sales representative. About Medexus Pharmaceuticals Inc. Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action. For more information, please contact: Ken d’Entremont, Chief Executive OfficerMedexus Pharmaceuticals Inc.Tel.: 905-676-0003E-mail: ken.dentremont@medexus.com Roland Boivin, Chief Financial OfficerMedexus Pharmaceuticals Inc.Tel.: 514-344-8765E-mail: roland.boivin@medexus.com Investor Relations (U.S.):Crescendo Communications, LLCTel: +1-212-671-1020E-mail: mdp@crescendo-ir.com Investor Relations (Canada):Tina ByersAdelaide Capital Tel: 905-330-3275E-mail: tina@adcap.ca Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.